CTR & CAT: The Use of Validated Tools in COPD Management
Webinar recorded July 20, 2022
Sponsored by GSK
Chronic obstructive pulmonary disease (COPD) affects 1 in 8 Americans 45 years of age and older. COPD results in ~15.4 million physician visits, ~1.5 million emergency department visits, and >700,000 hospitalizations annually. Hospitalizations for exacerbations account for ~70% of the ~$50 billion in annual expenditures for COPD. Additionally, COPD maintenance therapy remains underutilized, even after an exacerbation, and adherence to these medications has been shown to be poor.
The COPD Treatment Ratio (CTR) and the COPD Assessment Test (CAT) are two validated tools that can be used to help optimize management of COPD. This educational program will assist population-based decision makers with enhancing their understanding of how the CTR can be used to promote medication management and adherence to COPD medications and how the CAT can be utilized to identify patients at risk for exacerbation and promote the use of appropriate treatments.
This program will review:
- The COPD Treatment Ratio (CTR) from development to validation
- The COPD Assessment Test (CAT) and how it can be used to monitor patient health status, predict exacerbations, and guide management in COPD
At the end of the program, attendees should be able to:
- Understand the importance of improving patient care in COPD
- Understand the landscape of quality measure in COPD
- Describe two validated COPD management tools, the CTR and CAT
- Understand how implementation of validated tools, such as the CTR and CAT, can aid in COPD diagnosis and management
- Charlene E. McEvoy, MD, MPH
Pulmonary and Sleep Medicine
Medical Director Regions Sleep Health and Asthma Centers
Assistant Professor of Medicine, University of Minnesota
Investigator, HealthPartners Institute
- Judy Shepard Kelloway, BS, PharmD, HECON-C
Field Medical Account Lead - West, US Medical Affairs, GSK
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not AMCP.